Entresto patent expiry europe?

There isn’t a single “Entresto expiry” date in Europe. Entresto (sacubitril/valsartan) is protected by multiple patent families and regulatory exclusivities, so expiry depends on the specific patent or certificate and the country.

- The key protection is usually the fixed‑dose combination composition patent for sacubitril/valsartan, plus patents on related salts/crystal forms and manufacturing.
- In Europe, these patents are typically expected to run into the late 2020s (roughly 2027–2029 in many jurisdictions), but exact expiry varies by country and by whether any supplementary protection certificates (SPCs) or national continuations extend protection.
- In addition to patents, there can be regulatory data exclusivity which can delay generic entry beyond the patent expiry date.

If you want a precise expiry date for a specific European country (e.g., Germany, France, UK, etc.), tell me the country and I can outline the relevant patent families and current status for that jurisdiction. I can also guide you to the right patent databases (Espacenet, European Patent Register, SPC Register) to verify the exact dates.